Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing

E. Kay, A. O'Grady, J. M. Morgan, S. Wozniak, B. Jasani

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Aims: To evaluate the use of tissue microarray (TMA) technology as a validation tool for HER2 testing by both immunocytochemistry (ICC) and fluorescence in situ hybridisation (FISH) in the diagnostic setting. Methods: TMA constructs from 57 cases of breast cancer were evaluated for HER2 (by ICC and FISH) by two centres. The results were compared. Results: There was a high level of concordance for both ICC and FISH. In five "discrepant" cases only three would have had a potential impact on patient management. Conclusions: Validation of HER2 analysis in the clinical setting by ICC and FISH is essential. The use of TMAs provides for an economy of scale and would be practical in the setting of interlaboratory and intralaboratory validation. It is suggested that routine HER2 ICC and FISH should continue to be performed in laboratories on whole sections. Following this, TMAs would be constructed for all cases of breast cancer. ICC and FISH would be performed on these to validate the results. The TMAs would be available for circulation to other centres for validation purposes. The standardisation of testing between centres, the potential difficulty of minimum case numbers, and the workload issues surrounding validation would all be facilitated by this approach.

Original languageEnglish
Pages (from-to)1140-1144
Number of pages5
JournalJournal of Clinical Pathology
Volume57
Issue number11
DOIs
Publication statusPublished - Nov 2004
Externally publishedYes

Fingerprint

Fluorescence In Situ Hybridization
Immunohistochemistry
Breast Neoplasms
Workload
Technology

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing. / Kay, E.; O'Grady, A.; Morgan, J. M.; Wozniak, S.; Jasani, B.

In: Journal of Clinical Pathology, Vol. 57, No. 11, 11.2004, p. 1140-1144.

Research output: Contribution to journalArticle

Kay, E. ; O'Grady, A. ; Morgan, J. M. ; Wozniak, S. ; Jasani, B. / Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing. In: Journal of Clinical Pathology. 2004 ; Vol. 57, No. 11. pp. 1140-1144.
@article{93bcc44f75f146ada1ae6ecc1ce48e12,
title = "Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing",
abstract = "Aims: To evaluate the use of tissue microarray (TMA) technology as a validation tool for HER2 testing by both immunocytochemistry (ICC) and fluorescence in situ hybridisation (FISH) in the diagnostic setting. Methods: TMA constructs from 57 cases of breast cancer were evaluated for HER2 (by ICC and FISH) by two centres. The results were compared. Results: There was a high level of concordance for both ICC and FISH. In five {"}discrepant{"} cases only three would have had a potential impact on patient management. Conclusions: Validation of HER2 analysis in the clinical setting by ICC and FISH is essential. The use of TMAs provides for an economy of scale and would be practical in the setting of interlaboratory and intralaboratory validation. It is suggested that routine HER2 ICC and FISH should continue to be performed in laboratories on whole sections. Following this, TMAs would be constructed for all cases of breast cancer. ICC and FISH would be performed on these to validate the results. The TMAs would be available for circulation to other centres for validation purposes. The standardisation of testing between centres, the potential difficulty of minimum case numbers, and the workload issues surrounding validation would all be facilitated by this approach.",
author = "E. Kay and A. O'Grady and Morgan, {J. M.} and S. Wozniak and B. Jasani",
year = "2004",
month = "11",
doi = "10.1136/jcp.2003.014910",
language = "English",
volume = "57",
pages = "1140--1144",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing

AU - Kay, E.

AU - O'Grady, A.

AU - Morgan, J. M.

AU - Wozniak, S.

AU - Jasani, B.

PY - 2004/11

Y1 - 2004/11

N2 - Aims: To evaluate the use of tissue microarray (TMA) technology as a validation tool for HER2 testing by both immunocytochemistry (ICC) and fluorescence in situ hybridisation (FISH) in the diagnostic setting. Methods: TMA constructs from 57 cases of breast cancer were evaluated for HER2 (by ICC and FISH) by two centres. The results were compared. Results: There was a high level of concordance for both ICC and FISH. In five "discrepant" cases only three would have had a potential impact on patient management. Conclusions: Validation of HER2 analysis in the clinical setting by ICC and FISH is essential. The use of TMAs provides for an economy of scale and would be practical in the setting of interlaboratory and intralaboratory validation. It is suggested that routine HER2 ICC and FISH should continue to be performed in laboratories on whole sections. Following this, TMAs would be constructed for all cases of breast cancer. ICC and FISH would be performed on these to validate the results. The TMAs would be available for circulation to other centres for validation purposes. The standardisation of testing between centres, the potential difficulty of minimum case numbers, and the workload issues surrounding validation would all be facilitated by this approach.

AB - Aims: To evaluate the use of tissue microarray (TMA) technology as a validation tool for HER2 testing by both immunocytochemistry (ICC) and fluorescence in situ hybridisation (FISH) in the diagnostic setting. Methods: TMA constructs from 57 cases of breast cancer were evaluated for HER2 (by ICC and FISH) by two centres. The results were compared. Results: There was a high level of concordance for both ICC and FISH. In five "discrepant" cases only three would have had a potential impact on patient management. Conclusions: Validation of HER2 analysis in the clinical setting by ICC and FISH is essential. The use of TMAs provides for an economy of scale and would be practical in the setting of interlaboratory and intralaboratory validation. It is suggested that routine HER2 ICC and FISH should continue to be performed in laboratories on whole sections. Following this, TMAs would be constructed for all cases of breast cancer. ICC and FISH would be performed on these to validate the results. The TMAs would be available for circulation to other centres for validation purposes. The standardisation of testing between centres, the potential difficulty of minimum case numbers, and the workload issues surrounding validation would all be facilitated by this approach.

UR - http://www.scopus.com/inward/record.url?scp=8444225812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8444225812&partnerID=8YFLogxK

U2 - 10.1136/jcp.2003.014910

DO - 10.1136/jcp.2003.014910

M3 - Article

VL - 57

SP - 1140

EP - 1144

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 11

ER -